Advertisement

Phase III KEYNOTE-522 trial meets dual primary endpoint of event-free survival in high-risk early-stage TNBC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III KEYNOTE-522 trial investigating Keytruda in combination with chemotherapy as neoadjuvant treatment and then continuing as an adjuvant treatment after surgery met its dual primary endpoint of event-free survival for the treatment of patients with high-risk early-stage triple-negative breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Advertisement
Advertisement